Expand IFRX Menu
IFRX MENU

IFRX Latest Press Releases

-- April 9, 2026 --

InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor Globe Newswire 7:30 AM

-- March 31, 2026 --

InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium Globe Newswire 7:30 AM

-- March 30, 2026 --

InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting Globe Newswire 7:30 AM

-- March 19, 2026 --

InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones Globe Newswire 7:30 AM

-- March 18, 2026 --

InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting Globe Newswire 7:30 AM

-- March 13, 2026 --

InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement Globe Newswire 5:00 PM

-- March 12, 2026 --

InflaRx to Report Full Year 2025 Results on March 19, 2026 Globe Newswire 7:30 AM

-- February 26, 2026 --

InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference Globe Newswire 7:30 AM

-- January 29, 2026 --

InflaRx Announces Participation in February Investor Conferences Globe Newswire 7:30 AM

-- January 8, 2026 --

InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation Globe Newswire 8:00 AM
InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation Globe Newswire 8:00 AM

-- December 30, 2025 --

InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum Globe Newswire 7:30 AM

-- December 11, 2025 --

InflaRx Announces International Nonproprietary Name of "Izicopan" for INF904 Globe Newswire 7:30 AM

-- November 10, 2025 --

InflaRx Reports Positive Phase 2a Data for INF904 in Hidradenitis Suppurative (HS) and Chronic Spontaneous Urticaria (CSU) Globe Newswire 7:30 AM
Market Data Delayed 15 Minutes